澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CLARITY PHARMACEUTICALS LTD

3.270

+0.37012.76%

成交量：246.04萬

成交額：778.38萬

市值：12.17億

市盈率：-16.23

高：3.280

開：2.900

低：2.900

收：2.900

52周最高：5.870

52周最低：1.430

股本：3.72億

流通股本：2.74億

量比：1.06

換手率：0.90%

股息：- -

股息率：- -

每股收益(TTM):-0.201

每股收益(LYR):-0.201

淨資產收益率：-54.37%

總資產收益率：-33.76%

市淨率：13.48

市盈率(LYR):-16.23

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Clarity Pharmaceuticals表示靶向銅診療產品及臨牀開發項目不受美國100%關税影響

CLARITY PHARMACEUTICALS LTD確認美國臨牀試驗的同位素及藥品製造商均設在美國本土

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CU6.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":3.27,"timestamp":1770700320000,"preClose":2.9,"halted":0,"volume":2460352,"delay":0,"changeRate":0.12758620689655176,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.201427,"marketStatus":"已收盤","change":0.37,"latestTime":"02-10 16:12:00 AEDT","open":2.9,"high":3.28,"low":2.9,"amount":7783824,"amplitude":0.131034,"askPrice":3.28,"askSize":6041,"bidPrice":3.26,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.201427,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.9,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":1.057738,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-33.76%","roe":"-54.37%","lyrEps":-0.201427,"volumeRatio":1.057738,"shares":372030071,"dividePrice":0,"high":3.28,"amplitude":0.131034,"preClose":2.9,"low":2.9,"week52Low":1.43,"pbRate":"13.48","psRate":"128.56","week52High":5.87,"institutionHeld":0,"latestPrice":3.27,"committee":-0.502549,"eps":-0.201427,"divideRate":0,"volume":2460352,"delay":0,"ttmEps":-0.201427,"open":2.9,"prevYearClose":3.38,"prevWeekClose":2.73,"prevMonthClose":3.07,"prevQuarterClose":3.38,"fiveDayClose":2.96,"twentyDayClose":3.85,"sixtyDayClose":4.39,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142166450","title":"Clarity Pharmaceuticals表示靶向銅診療產品及臨牀開發項目不受美國100%關税影響","url":"https://stock-news.laohu8.com/highlight/detail?id=1142166450","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142166450?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856278,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals宣布，公司的靶向铜诊疗产品以及相关临床开发项目将不会受到美国实施的100%关税政策影响。\n该公司强调，尽管面临新的贸易政策挑战，其核心业务运营和产品开发计划仍将按既定方向推进，确保为患者提供创新的诊疗解决方案不会因外部贸易环境变化而受到干扰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"1176194720","title":"CLARITY PHARMACEUTICALS LTD確認美國臨牀試驗的同位素及藥品製造商均設在美國本土","url":"https://stock-news.laohu8.com/highlight/detail?id=1176194720","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176194720?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 11:11","pubTimestamp":1758856277,"startTime":"0","endTime":"0","summary":"CLARITY PHARMACEUTICALS LTD日前宣布，该公司已确认为其美国临床试验站点提供服务的所有同位素和药物产品制造商均位于美国境内。\n这一确认表明，CLARITY PHARMACEUTICALS LTD在美国开展的临床试验项目将完全依托本土制造商的产能和服务，确保供应链的稳定性和合规性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CU6.AU\",params:#limit:6,delay:true,,,undefined,":[]}}